Miracle Mile Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Miracle Mile Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.25M	Sell	9,518 -316	-3%	-$147K	0.06%	208
2025 Q4	$4.46M	Buy	9,834 +759	+8%	+$327K	0.06%	202
2025 Q3	$3.55M	Buy	9,075 +1,040	+13%	+$435K	0.05%	222
2025 Q2	$3.58M	Buy	8,035 +1,467	+22%	+$676K	0.06%	194
2025 Q1	$3.18M	Buy	6,568 +785	+14%	+$366K	0.06%	169
2024 Q4	$2.33M	Sell	5,783 -33	-0.6%	-$15.3K	0.05%	209
2024 Q3	$2.7M	Buy	5,816 +756	+15%	+$363K	0.06%	162
2024 Q2	$2.37M	Buy	5,060 +590	+13%	+$256K	0.06%	172
2024 Q1	$1.87M	Buy	4,470 +1,479	+49%	+$625K	0.05%	191
2023 Q4	$1.22M	Buy	+2,991	New	+$1.1M	0.03%	224

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Miracle Mile Advisors's VRTX Position: Q1 2026 in Review

Miracle Mile Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 3.2% in Q1 2026, selling an estimated $147K and leaving 9,518 shares worth $4.25M. The position accounts for 0.06% of the portfolio, ranked #208.

Miracle Mile Advisors first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $4.46M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Miracle Mile Advisors held 9,518 shares of Vertex Pharmaceuticals worth $4.25M as of Q1 2026.
Miracle Mile Advisors sold 316 Vertex Pharmaceuticals shares in Q1 2026, an estimated $147K.
Vertex Pharmaceuticals made up 0.06% of Miracle Mile Advisors's portfolio in Q1 2026, its #208 holding.
Miracle Mile Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Miracle Mile Advisors's Vertex Pharmaceuticals position peaked at $4.46M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Miracle Mile Advisors's 13F filing for Q1 2026, filed 8 Apr 2026.